Use of inhibitors of phosphatase activity of soluble epoxide for the treatment of cardiometabolic diseases

The growing prevalence of obesity and type 2 diabetes complicates risk and clinical management by potentiating and/or exacerbating hypertension, hyperlipidemia, atherosclerosis and cardiomyopathy, leading to increasing use of the term “cardiometabolic disease” (CMD) to encompass the many facets of this complex syndrome. The inventors assessed the role of the soluble epoxide hydrolase (she) phosphatase domain in metabolism and cardiovascular system, by generating sEH phosphatase knock-in (KI) animals (rats). They unexpectedly revealed that inhibition of the phosphatase domain of sEH could improve cardiac systolic function, decrease body weight, increase insulin sensitivity. More over under high fat diet, the animals have a decreased body weight gain, were protected against the development of insulin resistance, hepatic steatosis and cardiac hypertrophy. Inhibition of the phosphatase domain of sEH could thus represent a new pharmacological target in the treatment of cardiometabolic diseases.

Patent Application number: European Procedure (Patents) (EPA) - 17 Sept. 2018 - 18 306 207.4
Hydrolase activity) Varennes Olivier et al. “The Metabolism of Epoxyeicosatrienoic Acids by Soluble Epoxide Hydrolase Is Protective against the Development of Vascular Calcification.” International journal of molecular sciences vol. 2112 4313. 17 Jun. 2020 doi:10.3390/ijms21124313



    Business Developper
    Aymeric Empereur
    Business Developer
    Patent filling date: null
    Rare disease: No
    Second indication: Yes

    You might also be interested in